期刊
PATHOLOGY RESEARCH AND PRACTICE
卷 218, 期 -, 页码 -出版社
ELSEVIER GMBH
DOI: 10.1016/j.prp.2020.153322
关键词
Gastric cancer; Immunosurveillance; Immunoescape; Immunotherapy; Adoptive cell therapy; Cancer vaccine; Immune checkpoint
类别
资金
- Zhejiang Medical Technology Plan Project [2017KY007]
Gastric cancer is the third leading cause of deaths and the fifth most common cancers worldwide. Traditional treatment approaches include chemotherapy, radiation, surgery, and targeted therapy. Immunotherapy has shown promising results, but the prognosis remains poor.
Gastric cancer is considered as the third leading cause of deaths and the fifth most common cancers worldwide. Common treatment approaches include chemotherapy, radiation, gastric resection and targeted therapies. The emergence of gastric cancer immunotherapy has already shown some promising results and have altered the therapeutic procedures. Now, different combination therapies as well as novel immunotherapies targeting new molecules have been proposed. Despite ongoing investigations on the therapeutic options and significant advancements in this regard, the disease is poorly prognosed. In fact, limited therapeutic options and delayed diagnosis lead to the progression, dissemination and metastasis of the disease. Current immunotherapies are mostly based on cytotoxic immunocytes, monoclonal antibodies and gene transferred vaccines. The use of Immune checkpoint inhibitors (ICIs) have grown rapidly. In this review, we aimed to explore perspective and progression of different approaches of immunotherapy in the treatment of GC and the clinical outcomes reported so far. We also summarized the tumor immunosurveillance and tumor immunoescape.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据